<DOC>
	<DOC>NCT01029847</DOC>
	<brief_summary>Investigation of wholebody MRI and circulating biomarkers of inflammation, cartilage and bone metabolism in patients with spondyloarthritis treated with adalimumab. Furthermore to compare ultrasound examination with wholebody MRI etc.</brief_summary>
	<brief_title>Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Spondyloarthritis (SpA) according to the new ASAS criteria for axial SpA BASDAI &gt; 40 mm despite NSAIDs Clinical indication for treatment with TNFalpha inhibitor Age &gt; 18 years old and &lt; 85 years old Sufficient contraception for women Capable of giving informed consent Capable of complying with the examination program of the protocol Pregnancy wish, pregnancy or breastfeeding DMARDs within 4 weeks prior to inclusion Oral, intraarticular or intramuscular glucocorticoid within 4 weeks prior to inclusion The use of other study drugs within 4 weeks prior to inclusion or less than 5 halflives of the study drug before inclusion if this is more than 4 weeks The use of suspected diseasemodifying or immunosuppressive drugs within 4 weeks prior to inclusion DMARDs are allowed during the study, but the dose cannot be changed from 4 weeks prior to inclusion through week Contraindications for TNFÎ± inhibitor treatment Contraindications for MRI Known recent drug or alcohol abuse Failure to provide written consent Incapable of complying with the examination program for physical or mental reasons</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Patients with axial spondyloarthritis</keyword>
</DOC>